Systemic Immunomodulatory Effects of Combinatorial Treatment of Thalidomide and Dexamethasone on T Cells and Other Immune Cells

키워드

참고문헌 (46)

1. Gillett NA, "Applications of immunohistochemistry in the evaluation of immunosuppressive agents", Hum Exp Toxicol, 19, pp.251~254 (2000)
2. Tsuda K, "Calcineurin inhibitors suppress cytokine production from memory T cells and differentiation of naive T cells into cytokineproducing mature T cells", PLoS One, 7, pp.e31465~ (2012)
3. Chakkera HA, "Negative cardiovascular consequences of small molecule immunosuppressants", Clin Pharmacol Ther, 102, pp.269~276 (2017)
4. Humbert P, "Immune modulation by transplanted calcium phosphate biomaterials and human mesenchymal stromal cells in bone regeneration", Front Immunol, 10, pp.663~ (2019)
5. Navegantes KC, "Immune modulation of some autoimmune diseases : the critical role of macrophages and neutrophils in the innate and adaptive immunity", J Transl Med, 15, pp.36~ (2017)
6. Kim EJ, "Enhanced immune-modulatory effects of thalidomide and dexamethasone co-treatment on T cell subsets", Immunology, 152, pp.628~637 (2017)
7. Chen C, "Anti-inflammatory thalidomide improves islet grafts survival and functions in a xenogenic environment", Plos One, 4, pp.e6312~ (2009)
8. Chaves DN, "Assessment of immunossupresion induced by thalidomide, cyclosporine and diclofenac on skin allograft survival in rabbits", Rev Assoc Med Bras(1992), 54, pp.42~47 (2008)
9. Carvalho JB, "Effects of immunosuppression induced by thalidomide and cyclosporine in heterotopic heart transplantation in rabbits", Transplant Proc, 39, pp.1640~1641 (2007)
10. de Carvalho JB, "Efficacy of thalidomide as immunossupressor in heterotopic heart transplantation", Chirurgia(Bucur), 103, pp.429~434 (2008)
11. Bersani-Amado LE, "Involvement of cytokines in the modulation and progression of renal fibrosis induced by unilateral ureteral obstruction in C57BL", 6 mice : effects of thalidomide and dexamethasone, 2016, pp.30, 35~46
12. Kim BS, "Immune modulatory effect of thalidomide on T cells", Transplant Proc, 47, pp.787~790 (2015)
13. Lee SW, "Attenuation of nephritis in lupus-prone mice by thalidomide", Rheumatology(Oxford), 51, pp.2131~2140 (2012)
14. Tseng CM, "The suppression effects of thalidomide on human lung fibroblasts : cell proliferation, vascular endothelial growth factor release, and collagen production", Lung, 191, pp.361~368 (2013)
15. Vallet S, "Thalidomide and lenalidomide : mechanism-based potential drug combinations", Leuk Lymphoma, 49, pp.1238~1245 (2008)
16. Majumdar S, "Thalidomide suppresses NF-kappa B activation induced by TNF and H2O2, but not that activated by ceramide, lipopolysaccharides, or phorbol ester", J Immunol, 168, pp.2644~2651 (2002)
17. Kim BS, "Role of thalidomide on the expression of OX40, 4-1BB, and GITR in T cell subsets", Transplant Proc, 48, pp.1270~1274 (2016)
18. Suzuki S, "Dexamethasone upregulates 11beta-hydroxysteroid dehydrogenase type 2 in BEAS-2B cells", Am J Respir Crit Care Med, 167, pp.1244~1249 (2003)
19. Prado C, "Dexamethasone upregulates FOXP3 expression without increasing regulatory activity", Immunobiology, 216, pp.386~392 (2011)
20. Wang XQ, "Low-dose dexamethasone alleviates lipopolysaccharide-induced acute lung injury in rats and upregulates pulmonary glucocorticoid receptors", Respirology, 13, pp.772~780 (2008)
21. Chan ED, "Use of glucocorticoids in the critical care setting : science and clinical evidence", Pharmacol Ther, pp.107428~ (2020)
22. Oray M, "Longterm side effects of glucocorticoids", Expert Opin Drug Saf, 15, pp.457~465 (2016)
23. Schäcke H, "Mechanisms involved in the side effects of glucocorticoids", Pharmacol Ther, 96, pp.23~43 (2002)
24. Amador-Medina LF, "Thalidomide and dexamethasone induction therapy until best response in recently diagnosed patients with multiple myeloma : results from a pilot study", Rev Invest Clin, 67, pp.304~312 (2015)
25. Zamagni E, "Long-term results of thalidomide and dexamethasone(thaldex)as therapy of first relapse in multiple myeloma", Ann Hematol, 91, pp.419~426 (2012)
26. Takashima S, "Combination of bortezomib, thalidomide, and dexamethasone(VTD)as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients", Int J Hematol, 100, pp.159~164 (2014)
27. Wang C, "Down-modulation of programmed death 1 alters regulatory T cells and promotes experimental autoimmune encephalomyelitis", J Neurosci Res, 88, pp.7~15 (2010)
28. Francisco LM, "The PD-1 pathway in tolerance and autoimmunity", Immunol Rev, 236, pp.219~242 (2010)
29. Sage PT, "Dendritic cell PD-L1 limits autoimmunity and follicular T cell differentiation and function", J Immunol, 200, pp.2592~2602 (2018)
30. Buchbinder EI, "CTLA-4 and PD-1 pathways : similarities, differences, and implications of their inhibition", Am J Clin Oncol, 39, pp.98~106 (2016)
31. Fife BT, "Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways", Immunol Rev, 224, pp.166~182 (2008)
32. McCoy KD, "The role of CTLA-4 in the regulation of T cell immune responses", Immunol Cell Biol, 77, pp.1~10 (1999)
33. Takahashi T, "Immunologic self-tolerance maintained by CD25(+)CD4(+)regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4", J Exp Med, 192, pp.303~310 (2000)
34. Ganji A, "Increased expression of CD8 marker on T-cells in COVID-19 patients", Blood Cells Mol Dis, 83, pp.102437~ (2020)
35. Xiao Z, "Detuning CD8 T cells : downregulation of CD8 expression, tetramer binding, and response during CTL activation", J Exp Med, 204, pp.2667~2677 (2007)
36. Li W, "Significant decrease in peripheral regulatory B cells is an immunopathogenic feature of dermatomyositis", Sci Rep, 6, pp.27479~ (2016)
37. Morbach H, "CD19 controls Toll-like receptor 9 responses in human B cells", J Allergy Clin Immunol, 137, pp.889~898 (2016)
38. Kim JH, "CD11c(hi)dendritic cells regulate Ly-6C(hi)monocyte differentiation to preserve immune-privileged CNS in lethal neuroinflammation", Sci Rep, 5, pp.17548~ (2015)
39. Wu J, "Critical role of integrin CD11c in splenic dendritic cell capture of missing-self CD47cells to induce adaptive immunity", Proc Natl Acad Sci U S A, 115, pp.6786~6791 (2018)
40. Walker LS, "Treg and CTLA-4 : two intertwining pathways to immune tolerance", J Autoimmun, 45, pp.49~57 (2013)
41. Read S, "Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+)regulatory cells that control intestinal inflammation", J Exp Med, 192, pp.295~302 (2000)
42. Xia M, "Dexamethasone enhances CTLA-4 expression during T cell activation", Cell Mol Life Sci, 55, pp.1649~1656 (1999)
43. Giles AJ, "Dexamethasone-induced immunosuppression : mechanisms and implications for immunotherapy", J Immunother Cancer, 6, pp.51~ (2018)
44. Crepeau RL, "Challenges and opportunities in targeting the CD28", CTLA-4 pathway in transplantation and autoimmunity, 2017, pp.17, 1001~1012
45. Wu J, "Expression and function of immunoglobulinlike transcripts on tolerogenic dendritic cells", Hum Immunol, 70, pp.353~356 (2009)
46. Manavalan JS, "High expression of ILT3 and ILT4 is a general feature of tolerogenic dendritic cells", Transpl Immunol, 11, pp.245~258 (2003)

관련 논문AI추천